Pfizer Inc (PFE)

Total asset turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	63,627,000	60,113,000	55,643,000	55,094,000	58,497,000	68,538,000	77,944,000	92,952,000	100,331,000	99,879,000	101,335,000	92,570,000	81,491,000	69,337,000	57,374,000	50,198,000	47,644,000	48,648,000	49,197,000	50,660,000
Total assets	US$ in thousands	213,396,000	219,476,000	216,193,000	221,095,000	226,501,000	215,021,000	220,168,000	195,617,000	197,206,000	195,349,000	195,290,000	183,841,000	181,477,000	179,188,000	169,920,000	158,818,000	154,229,000	178,983,000	177,934,000	166,336,000
Total asset turnover		0.30	0.27	0.26	0.25	0.26	0.32	0.35	0.48	0.51	0.51	0.52	0.50	0.45	0.39	0.34	0.32	0.31	0.27	0.28	0.30

December 31, 2024 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $63,627,000K ÷ $213,396,000K
= 0.30

Total asset turnover measures how efficiently a company generates revenue from its assets. For Pfizer Inc, the total asset turnover ratio has fluctuated over the past few years. The ratio stood at 0.30 as of March 31, 2020, indicating that the company generated $0.30 in revenue for every dollar of assets. It decreased to 0.28 by June 30, 2020, and continued to decline gradually to 0.26 by March 31, 2024.

There was a slight improvement in the ratio by June 30, 2024, reaching 0.26, although it remained relatively low. This suggests that Pfizer Inc may not be efficiently utilizing its assets to generate revenue during this period. Overall, the trend indicates some inconsistency in how effectively the company is generating sales from its asset base, warranting further analysis to identify potential areas for improvement in asset utilization.